JPWO2019229536A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019229536A5 JPWO2019229536A5 JP2020566662A JP2020566662A JPWO2019229536A5 JP WO2019229536 A5 JPWO2019229536 A5 JP WO2019229536A5 JP 2020566662 A JP2020566662 A JP 2020566662A JP 2020566662 A JP2020566662 A JP 2020566662A JP WO2019229536 A5 JPWO2019229536 A5 JP WO2019229536A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- pharmaceutically acceptable
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000005647 linker group Chemical group 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001302 tertiary amino group Chemical group 0.000 claims description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000001993 dienes Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- -1 CanAg Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677498P | 2018-05-29 | 2018-05-29 | |
| US62/677,498 | 2018-05-29 | ||
| PCT/IB2019/000691 WO2019229536A2 (en) | 2018-05-29 | 2019-05-29 | Novel benzodiazepine derivatives and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525730A JP2021525730A (ja) | 2021-09-27 |
| JP2021525730A5 JP2021525730A5 (https=) | 2022-06-07 |
| JPWO2019229536A5 true JPWO2019229536A5 (https=) | 2022-06-07 |
| JP7465819B2 JP7465819B2 (ja) | 2024-04-11 |
Family
ID=68692822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566662A Active JP7465819B2 (ja) | 2018-05-29 | 2019-05-29 | 新規ベンゾジアゼピン誘導体及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11084801B2 (https=) |
| EP (1) | EP3802546A4 (https=) |
| JP (1) | JP7465819B2 (https=) |
| KR (1) | KR102946423B1 (https=) |
| CN (2) | CN113444111A (https=) |
| AU (2) | AU2019276833A1 (https=) |
| BR (1) | BR112020023623A2 (https=) |
| CA (1) | CA3100141A1 (https=) |
| EA (1) | EA202092909A1 (https=) |
| IL (1) | IL278973B2 (https=) |
| MX (1) | MX2020012718A (https=) |
| WO (1) | WO2019229536A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008441A1 (en) | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
| MX2020012718A (es) | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| KR20210068591A (ko) | 2018-10-31 | 2021-06-09 | 주식회사 인투셀 | 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도 |
| EP3906064A4 (en) * | 2019-01-03 | 2023-03-08 | Intocell, Inc. | CLEAVABLE LINKER COMPOUNDS AND USES THEREOF |
| WO2020141460A2 (en) | 2019-01-03 | 2020-07-09 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
| KR20220108783A (ko) * | 2019-12-02 | 2022-08-03 | 주식회사 인투셀 | 분자 접합과 관련된 조성물 및 방법 |
| KR20230028793A (ko) * | 2020-06-26 | 2023-03-02 | 주식회사 인투셀 | 항-b7-h3 항체를 포함하는 항체-약물 접합체 |
| CN114805432A (zh) * | 2022-03-03 | 2022-07-29 | 西北工业大学 | 新型可光催化剪切的羧酸保护基及其氨基酸衍生物的制备方法 |
| CN119424671A (zh) | 2023-08-01 | 2025-02-14 | 上海新理念生物医药科技有限公司 | 含糖基吡啶型连接子的抗体药物偶联物 |
| WO2025262641A1 (en) * | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843937A (en) | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| CA2850103C (en) * | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013055993A1 (en) * | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| HK1211208A1 (zh) | 2012-08-22 | 2016-05-20 | Immunogen, Inc. | 細胞毒性苯並二氮呯衍生物 |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| RU2729194C2 (ru) * | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| TW201632531A (zh) * | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | 苯二氮呯二聚物，其結合物及製造與使用方法 |
| JP6676058B2 (ja) * | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| MX382582B (es) | 2015-03-18 | 2025-03-13 | Seagen Inc | Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados. |
| US9504694B2 (en) * | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| JP2019516705A (ja) * | 2016-05-20 | 2019-06-20 | アッヴィ・ステムセントルクス・エル・エル・シー | 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート |
| WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| AU2018237683A1 (en) * | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2019008441A1 (en) * | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
| GB201714115D0 (en) * | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
| MX2020012718A (es) | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| KR20210068591A (ko) | 2018-10-31 | 2021-06-09 | 주식회사 인투셀 | 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도 |
| KR102503143B1 (ko) | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| KR20230028793A (ko) | 2020-06-26 | 2023-03-02 | 주식회사 인투셀 | 항-b7-h3 항체를 포함하는 항체-약물 접합체 |
-
2019
- 2019-05-29 MX MX2020012718A patent/MX2020012718A/es unknown
- 2019-05-29 IL IL278973A patent/IL278973B2/en unknown
- 2019-05-29 EA EA202092909A patent/EA202092909A1/ru unknown
- 2019-05-29 AU AU2019276833A patent/AU2019276833A1/en not_active Abandoned
- 2019-05-29 WO PCT/IB2019/000691 patent/WO2019229536A2/en not_active Ceased
- 2019-05-29 CA CA3100141A patent/CA3100141A1/en active Pending
- 2019-05-29 CN CN202110592302.2A patent/CN113444111A/zh active Pending
- 2019-05-29 JP JP2020566662A patent/JP7465819B2/ja active Active
- 2019-05-29 BR BR112020023623-3A patent/BR112020023623A2/pt unknown
- 2019-05-29 EP EP19811692.3A patent/EP3802546A4/en active Pending
- 2019-05-29 KR KR1020207037031A patent/KR102946423B1/ko active Active
- 2019-05-29 US US16/425,237 patent/US11084801B2/en active Active
- 2019-05-29 CN CN201980035084.3A patent/CN112166115A/zh active Pending
-
2021
- 2021-06-30 US US17/363,814 patent/US11807628B2/en active Active
-
2023
- 2023-06-05 AU AU2023203485A patent/AU2023203485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525730A5 (https=) | ||
| CN114456186B (zh) | 一种喜树碱类衍生物及其配体-药物偶联物 | |
| FI105155B (fi) | Menetelmä terapeuttisesti käyttökelpoisten sappihappojohdannaisten valmistamiseksi | |
| Chari et al. | Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation | |
| JP2020527599A5 (https=) | ||
| US5877210A (en) | Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | |
| JP6474404B2 (ja) | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 | |
| CN111093711A (zh) | 可编程的树枝状药物 | |
| JP2006523237A5 (https=) | ||
| MX2013013069A (es) | Conjugados de proteina-agente activo y método para su preparación. | |
| JP2006523237A (ja) | Ｐｉ−３キナーゼインヒビタープロドラッグ | |
| AU2022267394B2 (en) | Anti-c-met antibody drug conjugates | |
| JPWO2019140301A5 (https=) | ||
| JPWO2019229536A5 (https=) | ||
| KR20180030993A (ko) | 항체-약물 접합체 중의 공유결합 링커 및 이의 제조방법 및 사용방법 | |
| JP2005507857A (ja) | 改変ｐｓｍａリガンド及びそれに関する利用 | |
| JP2022552757A (ja) | カンプトテシン類医薬品及びその抗体複合体 | |
| JP2018512424A (ja) | エステル化のための試薬及び方法 | |
| JPWO2020236817A5 (https=) | ||
| JP2017506628A (ja) | がん及び炎症性疾患の治療のための結合体及びプロドラッグ | |
| US9592219B2 (en) | Self-magnetic metal-salen complex compound | |
| JPWO2020089687A5 (https=) | ||
| Makarov et al. | Modification of 3, 5-bis (arylidene)-4-piperidone pharmacophore by phosphonate group using 1, 2, 3-triazole cycle as a linker for the synthesis of new cytostatics | |
| KR102435905B1 (ko) | 스테로이드 수용체 공활성제의 소분자 조절제 및 이의 사용 방법 | |
| CN118059261A (zh) | 一种用于预防肿瘤骨转移的纳米材料及其制备方法和应用 |